|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/05 | |
| A61K 31/19 | |||
| A61K 31/4015 | |||
| A61P 25/08 |
| (11) | Number of the document | 2661263 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12700294.7 |
| Date of filing the European patent application | 2012-01-03 | |
| (97) | Date of publication of the European application | 2013-11-13 |
| (45) | Date of publication and mention of the grant of the patent | 2021-04-14 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2012/050002 |
| Date | 2012-01-03 |
| (87) | Number | WO 2012/093255 |
| Date | 2012-07-12 |
| (30) | Number | Date | Country code |
| 201100043 | 2011-01-04 | GB |
| (72) |
WHALLEY, Benjamin, GB
WILLIAMS, Claire, GB
STEPHENS, Gary, GB
|
| (73) |
Otsuka Pharmaceutical Co., Ltd.,
9, Kanda-Tsukasamachi 2-chome Chiyoda-ku, Tokyo 101-8535,
JP
GW Pharma Limited, Sovereign House, Histon Cambridge CB24 9BZ, GB |
| (54) | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY |
| USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY |